How To Choose A College In The Age Of AI

Along with cost and payoff, families should consider how colleges are responding—and preparing students—to thrive as artificial intelligence reshapes education and jobs,

Forbes’ Top 25 Public Colleges

These public universities, seven in California, produce strong academic and career outcomes while charging state residents far lower tuition than private schools.

AI Isn’t Replacing Stock Brokers– It’s Making Them Better

Artificial Intelligence was supposed to make financial advisors obsolete. Instead, it is helping them be more productive than ever.

A Tiny Startup Helping Google Take On Nvidia Is Now Worth $18 Billion

A little-known company called Fluidstack has become a test bed for Google’s plans to push its own AI chip. That’s helped it hit a $18 billion valuation and minted its founders as new billionaires.

How NBA Journeyman Omri Casspi Built An $800 Million Venture Capital Firm

Former NBA role player Omri Casspi has already scored with investments in startups like Cognition and Eon. Now, his Swish Ventures is launching a $250 million fund.

Meet The Ex-OpenAI Guys Building A Cheaper Open Source Alternative

Just 15 months after it founding, Applied Compute is raising $350 million at a $3.25 billion valuation, nearly double its worth from four months ago.

Prompts On The Playa: AI Invades Burning Man

Silicon Valley brought sushi, Starlink and luxury camps to Burning Man. Now it’s importing something potentially even more divisive: AI slop.

Josh Kushner’s Fortune Tripled This Year Thanks To Stakes In OpenAI, SpaceX And More

The Kushner scion’s VC firm Thrive Capital nearly tripled its assets thanks to smart bets on OpenAI and SpaceX. Now he’s looking to spend some cash on the NBA’s Lakers.

TikTok Profits Off Drug Dealer Ads For Cocaine, Opioids And Xanax

The Chinese-owned social network has been flooded with advertisements pushing street drugs and prescription pills like codeine, benzos and Adderall.

Italy’s $10 Billion Pharma Family Makes A U.S. Power Move

For four generations, Rome’s Angelini family has built a $2.5 billion operation with drugs for depression and epilepsy in Europe. Now it’s bought its way into the U.S. market.